<DOC>
	<DOCNO>NCT00020176</DOCNO>
	<brief_summary>RATIONALE : Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy use kill tumor cell . PURPOSE : Phase II trial study effectiveness allogeneic peripheral stem cell transplantation treat patient stage IV breast cancer .</brief_summary>
	<brief_title>Allogeneic Peripheral Stem Cell Transplantation Treating Patients With Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine ability T-cell-depleted allogeneic blood stem cell transplantation immunoablative conditioning regimen induce state mixed host/donor chimerism patient metastatic breast cancer . - Determine ability treatment regimen induce allogeneic graft-versus-tumor response patient . - Determine feasibility give approved therapy patient first sign disease progression order stabilize produce minimal partial response . OUTLINE : Patients receive chemotherapy comprise fludarabine IV 30 minute cyclophosphamide IV 1 hour day 1-4 . Patients receive filgrastim ( G-CSF ) SC daily begin day 5 continue blood count recover . Treatment repeat every 21 day maximum 2 course . Patients receive transplantation preparative regimen comprise fludarabine IV 30 minute cyclophosphamide IV 2 hour day -6 -3 ( begin day 22 immune-depleting chemotherapy ) follow allogeneic peripheral blood stem cell transplantation IV day 0 . Patients receive G-CSF SC daily begin day 0 continue blood count recover , plus cyclosporine IV 1-2 hour every 12 hour day -1 14 orally day 40 . Patients persistent malignant disease less grade II acute graft-versus-host disease receive donor lymphocytes IV day 42 , 70 , 98 . Patients follow twice weekly day 100 , 6 , 9 , 12 , 18 , 24 month . PROJECTED ACCRUAL : A maximum 70 patient accrue study within 24 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Stage IV breast cancer Measurable disease Progressive disease Increase disease mass less partial response therapy At least one prior chemotherapy regimen metastatic disease progress Must receive prior therapy taxane anthracycline Estrogen/progesterone receptorpositive patient must receive progress least one hormonal agent adjuvant metastatic set Her2neuexpressing patient must receive progressed trastuzumab ( Herceptin® ) adjuvant metastatic setting Prior autologous stem cell transplantation allow less complete response disease progression adjuvant metastatic set Consenting firstdegree relative least 5 6 HLAantigen match ( may include mismatch D locus ) Hormone receptor status : Estrogen receptor status know Progesterone receptor status know PATIENT CHARACTERISTICS : Age : 18 70 Sex : Male female Menopausal status : Not specify Performance status : Karnofsky 80100 % Life expectancy : More 6 month Hematopoietic : Not specify Hepatic : Bilirubin ≤ 2 mg/dL SGOT &lt; 4 time upper limit normal Hepatitis B surface antigen negative Hepatitis C antibody negative Renal : Creatinine ≤ 1.5 mg/dL Creatinine clearance ≥ 50 mL/min Cardiovascular : Left ventricular ejection fraction &gt; 45 % Pulmonary : DLCO ≥ 50 % predict Other : HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Recovered prior stem cell transplantation Chemotherapy : See Disease Characteristics Endocrine therapy : See Disease Characteristics No concurrent steroid Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2004</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>